H.pylori gastritis guideline recommendation

Helicobacter pylori infection Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology Gastritis Peptic ulcer disease Gastric adenocarcinoma MALT lymphoma
Causes
Differentiating Helicobacter pylori infection from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Guideline Recommendation ACG guidelines ESPGHAN and NASPGHAN guidelines
History and Symptoms
Physical Examination
Diagnostic tests Endoscopic tests Nonendoscopic tests
Electrocardiogram
X Ray
CT
MRI
Ultrasound
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
H.pylori gastritis guideline recommendation On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of H.pylori gastritis guideline recommendation All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on H.pylori gastritis guideline recommendation
CDC on H.pylori gastritis guideline recommendation
H.pylori gastritis guideline recommendation in the news
Blogs on H.pylori gastritis guideline recommendation
Directions to Hospitals Treating Helicobacter pylori infection
Risk calculators and risk factors for H.pylori gastritis guideline recommendation

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yamuna Kondapally, M.B.B.S[2]

ACG recommendations

Recommendation
Testing for H. pylori infection is indicated in patients with active peptic ulcer disease, a past history of documented peptic ulcer, or gastric MALT lymphoma.
The test-and-treat strategy for H. pylori infection is a proven management strategy for patients with uninvestigated dyspepsia who are under the age of 55 yr and have no “alarm features” (bleeding, anemia, early satiety, unexplained weight loss, progressive dysphagia, odynophagia, recurrent vomiting, family history of GI cancer, previous esophagogastric malignancy).